Inventurus Knowledge Solutions Limited has finalized the financing for its acquisition of TruBridge, Inc. through its subsidiary IKS Inc. The company announced the execution of a Facilities Agreement, a Pledge and Security Agreement, a Power of Attorney, and a Letter of Comfort. These agreements were finalized on July 3, 2026, involving various financial institutions and trustees, securing the acquisition and ensuring oversight of the subsidiary’s operations.
Financing Secured for TruBridge Acquisition
Inventurus Knowledge Solutions Limited (the “Company”) has announced the successful finalization of financing arrangements for the acquisition of TruBridge, Inc. (the “Target”) by its wholly-owned subsidiary, Inventurus Knowledge Solutions, Inc. (“IKS Inc.”). This marks a significant step in the “Proposed Acquisition” process.
Key Agreements Executed
On July 3, 2026, several crucial agreements were executed to facilitate the acquisition and provide necessary financing facilities. These include:
- A Facilities Agreement: This agreement, executed by the Company (as parent), IKS Inc. (as borrower), and various lenders and arrangers, outlines the terms of the financing. Key parties include Aquity Holdings, Inc., Aquity Solutions, LLC, Citigroup Global Markets Asia Limited, Deutsche Bank AG, Singapore Branch, JPMorgan Chase Bank, N.A., Hong Kong Branch, Citibank, N.A., Export-Import Bank of India, London Branch, and Axis Trustee Services Ltd.
- A Pledge and Security Agreement: Executed between the Company and Axis Trustee Services Ltd. (as Security Agent), this agreement pertains to the creation of security interests to back the facilities.
- A Power of Attorney: Also executed by the Company on July 3, 2026, appointing the Security Agent as its agent, proxy, and attorney-in-fact.
- A Letter of Comfort: Issued by the Company in favor of the Agent, confirming ongoing oversight of IKS Inc.’s governance, capital, and investment strategies.
Information Availability
The detailed information regarding these executed agreements is available on the Company’s website at https://ikshealth.com/investor-relations/.
Source: BSE
